AU2021349316A1 — Improvement of physical and mental well-being of patients with hypoparathyroidism
Assigned to Ascendis Pharma Bone Diseases AS · Expires 2023-04-27 · 3y expired
What this patent protects
The present invention relates to a sustained-release PTH compound for use in a method of improving and treating the physical and mental well-being of patients having hypoparathyroidism, wherein the sustained-release PTH compound releases PTH with a release half-life of at least 1…
USPTO Abstract
The present invention relates to a sustained-release PTH compound for use in a method of improving and treating the physical and mental well-being of patients having hypoparathyroidism, wherein the sustained-release PTH compound releases PTH with a release half-life of at least 12 hours. In another aspect the present invention relates to a method of improving physical and mental well-being of a patient having hypoparathyroidism, comprising administering to the patient a sustained-release PTH compound, wherein the sustained release PTH compound releases PTH with a release half-life of at least 12 hours thereby improving physical and mental well-being of the patient.
Drugs covered by this patent
- Yorvipath (PALOPEGTERIPARATIDE) · Ascendis Pharma Bone
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.